First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4589
Abstract: Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non‐squamous non‐small cell lung cancer (NS‐NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI… read more here.
Keywords: plus chemotherapy; ici chemotherapy; first line; bev chemotherapy ... See more keywords